Sacha Devillers

Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains. This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France. The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).

SciencePOD--which stands for Science Prose On-Demand--is the go-to site for specialist content creation solutions. SciencePOD connects clients requiring technically and scientifically accurate content in any format with a team of specialist Science Writers. SciencePOD adds the peace of mind of quality-controlled content delivered by our Editors and Proofreaders. We have a platform to fast track the editorial commissioning and content creation process, which also gives our Commissioning Editor access to our pre-vetted network of expert content creators. Outsourcing content creation is time-consuming and riddled with difficulties because it takes a lot of time and effort to find suitably qualified expert writers and editors able to explain complex matters in simple terms. We provide spare editorial capabilities to organisations connected to science, medicine, technology and innovation so that they can scale up their coverage. Specifically, we offer the extra help their team needs to deliver clear, concise, compelling content and showcase their work. Quality content matter because people involved in industries and activities related to research and innovation have a need to communicate in clear, concise, compelling language. This helps them be widely understood and make deals with business partners or innovation collaborators, get funding or fulfil the mandatory requirement to be accountable to society when publicly funded. This is precisely why SciencePOD was created. SciencePOD helps make those who matter value the work science-based organisations and science publishers do.

Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains. This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France. The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).

SciencePOD--which stands for Science Prose On-Demand--is the go-to site for specialist content creation solutions. SciencePOD connects clients requiring technically and scientifically accurate content in any format with a team of specialist Science Writers. SciencePOD adds the peace of mind of quality-controlled content delivered by our Editors and Proofreaders. We have a platform to fast track the editorial commissioning and content creation process, which also gives our Commissioning Editor access to our pre-vetted network of expert content creators. Outsourcing content creation is time-consuming and riddled with difficulties because it takes a lot of time and effort to find suitably qualified expert writers and editors able to explain complex matters in simple terms. We provide spare editorial capabilities to organisations connected to science, medicine, technology and innovation so that they can scale up their coverage. Specifically, we offer the extra help their team needs to deliver clear, concise, compelling content and showcase their work. Quality content matter because people involved in industries and activities related to research and innovation have a need to communicate in clear, concise, compelling language. This helps them be widely understood and make deals with business partners or innovation collaborators, get funding or fulfil the mandatory requirement to be accountable to society when publicly funded. This is precisely why SciencePOD was created. SciencePOD helps make those who matter value the work science-based organisations and science publishers do.

As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.